Trial Profile
A Phase I Study of Low Dose Subcutaneous Interleukin-2 (IL-2) For The Treatment of Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- 03 Aug 2021 Status changed from active, no longer recruiting to completed.
- 17 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 02 Oct 2020 Planned End Date changed from 1 Dec 2020 to 1 Jan 2021.